Pure Global
NCT06394492

SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer

A Randomized, Open-Label, Controlled, Phase III Study of SHR-A1921 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·Phase 3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Ovarian Cancer
Drug/Device/Intervention
SHR-A1921
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Location
Beijing,Hangzhou, China
Timeline & enrollment
Phase
Phase 3
Start date
May 31, 2024
End date
Dec 31, 2026
Enrollment
440 participants
Primary outcome

Progression-free Survival (PFS) assessed by site investigator as per RECIST 1.1

Summary

This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy
 and safety of SHR-A1921 versus investigator's choice of chemotherapy in patients with
 platinum-resistant recurrent epithelial ovarian cancer.

ICD-10 classifications
Malignant neoplasm of ovarySecondary malignant neoplasm of ovaryBenign neoplasm of ovaryOvarian pregnancyOvarian dysfunction
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06394492
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06394492 through Pure Global AI's free database. This Phase 3 trial is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. and is currently Not yet recruiting. The study focuses on Ovarian Cancer. Target enrollment is 440 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.